Active	Status	Sponsor type	Region	Phase	Filter
9 Active 0 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

9 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Engler, Tobias
ADAPTlate, NCT04565054 / 2019-001488-60: Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC	Recruiting	3	1260	Europe	Abemaciclib 50 MG; 150mg 1-0-1 per os, Verzenios	West German Study Group, Eli Lilly and Company, Genomic Health®, Inc.	Breast Cancer Female	06/28	07/29
ADAPTcycle, NCT04055493: Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC	Active, not recruiting	3	1684	Europe	Ribociclib 200Mg Oral Tablet, Kisqali	West German Study Group, Novartis, Genomic Health®, Inc.	Breast Cancer Female	07/27	07/27
ADAPTHER2-IV, NCT05704829: NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer	Recruiting	2	402	Europe	Trastuzumab deruxtecan, ENHERTU, Standard-of-Care, Chemotherapy+T+P	West German Study Group, AstraZeneca	HER2-positive Early Breast Cancer	06/26	06/28
ADAPT-TN-III, NCT06081244: NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC	Recruiting	2	348	Europe	Sacituzumab govitecan, Trodelvy, Pembrolizumab, Keytruda	West German Study Group, Gilead Sciences, Merck Sharp & Dohme LLC	Triple Negative Breast Cancer	09/29	09/29
ELEVATE, NCT05563220: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer	Recruiting	1/2	400	Europe, US, RoW	Elacestrant, Alpelisib, Piqray, Everolimus, Afinitor, Ribociclib, Kisqali, Palbociclib, Ibrance, Capivasertib, Truqap, Abemaciclib, Verzenio	Stemline Therapeutics, Inc.	Breast Cancer, Metastatic Breast Cancer	12/26	12/28
NCT05914974: Immunotherapy-related CRP Kinetics in Metastatic Gynecological Malignancies	Recruiting	N/A	120	Europe		University Hospital Tuebingen, University Hospital Ulm, University Hospital Freiburg	Gynecological Malignancies, Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Vulvar Cancer	04/25	04/35
NCT05914961: Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast Cancer	Recruiting	N/A	225	Europe		University Hospital Tuebingen, University Hospital Ulm, University Hospital Freiburg	TNBC - Triple-Negative Breast Cancer	04/25	04/35
Baila, Yasmin
ADAPTHER2-IV, NCT05704829: NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer	Recruiting	2	402	Europe	Trastuzumab deruxtecan, ENHERTU, Standard-of-Care, Chemotherapy+T+P	West German Study Group, AstraZeneca	HER2-positive Early Breast Cancer	06/26	06/28
ELEVATE, NCT05563220: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer	Recruiting	1/2	400	Europe, US, RoW	Elacestrant, Alpelisib, Piqray, Everolimus, Afinitor, Ribociclib, Kisqali, Palbociclib, Ibrance, Capivasertib, Truqap, Abemaciclib, Verzenio	Stemline Therapeutics, Inc.	Breast Cancer, Metastatic Breast Cancer	12/26	12/28

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Engler, Tobias
ADAPTlate, NCT04565054 / 2019-001488-60: Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC	Recruiting	3	1260	Europe	Abemaciclib 50 MG; 150mg 1-0-1 per os, Verzenios	West German Study Group, Eli Lilly and Company, Genomic Health®, Inc.	Breast Cancer Female	06/28	07/29
ADAPTcycle, NCT04055493: Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC	Active, not recruiting	3	1684	Europe	Ribociclib 200Mg Oral Tablet, Kisqali	West German Study Group, Novartis, Genomic Health®, Inc.	Breast Cancer Female	07/27	07/27
ADAPTHER2-IV, NCT05704829: NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer	Recruiting	2	402	Europe	Trastuzumab deruxtecan, ENHERTU, Standard-of-Care, Chemotherapy+T+P	West German Study Group, AstraZeneca	HER2-positive Early Breast Cancer	06/26	06/28
ADAPT-TN-III, NCT06081244: NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC	Recruiting	2	348	Europe	Sacituzumab govitecan, Trodelvy, Pembrolizumab, Keytruda	West German Study Group, Gilead Sciences, Merck Sharp & Dohme LLC	Triple Negative Breast Cancer	09/29	09/29
ELEVATE, NCT05563220: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer	Recruiting	1/2	400	Europe, US, RoW	Elacestrant, Alpelisib, Piqray, Everolimus, Afinitor, Ribociclib, Kisqali, Palbociclib, Ibrance, Capivasertib, Truqap, Abemaciclib, Verzenio	Stemline Therapeutics, Inc.	Breast Cancer, Metastatic Breast Cancer	12/26	12/28
NCT05914974: Immunotherapy-related CRP Kinetics in Metastatic Gynecological Malignancies	Recruiting	N/A	120	Europe		University Hospital Tuebingen, University Hospital Ulm, University Hospital Freiburg	Gynecological Malignancies, Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Vulvar Cancer	04/25	04/35
NCT05914961: Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast Cancer	Recruiting	N/A	225	Europe		University Hospital Tuebingen, University Hospital Ulm, University Hospital Freiburg	TNBC - Triple-Negative Breast Cancer	04/25	04/35
Baila, Yasmin
ADAPTHER2-IV, NCT05704829: NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer	Recruiting	2	402	Europe	Trastuzumab deruxtecan, ENHERTU, Standard-of-Care, Chemotherapy+T+P	West German Study Group, AstraZeneca	HER2-positive Early Breast Cancer	06/26	06/28
ELEVATE, NCT05563220: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer	Recruiting	1/2	400	Europe, US, RoW	Elacestrant, Alpelisib, Piqray, Everolimus, Afinitor, Ribociclib, Kisqali, Palbociclib, Ibrance, Capivasertib, Truqap, Abemaciclib, Verzenio	Stemline Therapeutics, Inc.	Breast Cancer, Metastatic Breast Cancer	12/26	12/28